insert therapeutics unidym tego bio sciences science research anti-cancer drugs RNAi therapeutics carbon-based electronics nanotechnology arrowhead pasadena california nasdaq arwr nanotechnology arrowhead pasadena california nasdaq arwr
PRESS RELEASE
April 15, 2010
Investor Relations Contacts:

Brandi Floberg
The Piacente Group, Inc.
212-481-2050
arrowres@tpg-ir.com

 


Arrowhead Regains Compliance with Rule 5550,
NASDAQ $1.00 Minimum Bid Requirement


PASADENA, Calif. – April 15, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on April 14, 2010, it received a notification from the NASDAQ Stock Market indicating that the Company has regained compliance with NASDAQ Rule 5550(a)(2) in that the Company's closing bid price has been at $1.00 per share or greater for at least 10 consecutive business days. The April 14, 2010 notification also stated that the matter of the deficiency, as set forth in the previously reported September 15, 2009 deficiency notice, is now closed.

 




About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.